This trial is testing whether a new glaucoma medication is as effective as the current standard medication.
1 Primary · 0 Secondary · Reporting Duration: up to Week12
Active Control
Experimental Treatment
500 Total Participants · 2 Treatment Groups
Primary Treatment: Bimatoprost Ophthalmic · No Placebo Group · Phase 3
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Pennsylvania | 100.0% |
18 - 65 | 100.0% |
Did not meet criteria | 100.0% |
1 | 100.0% |